Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects-Reference-Cited by-同舟云学术

Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects

Published:2016-11 Issue:11 Volume:34 Page:26-32
ISSN:0735-6757
Container-title:The American Journal of Emergency Medicine
language:en
Short-container-title:The American Journal of Emergency Medicine

Author:

Reilly Paul A.,van Ryn Joanne,Grottke Oliver,Glund Stephan,Stangier Joachim

Publisher

Elsevier BV

Subject

Emergency Medicine,General Medicine

Reference27 articles.

1. Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials;Liew;J Thromb Haemost,2014

2. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials;Ruff;Lancet,2014

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study;Cardiology and Therapy;2023-10-17

2. Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases;Research and Practice in Thrombosis and Haemostasis;2023-07

3. Review of Target-Specific Anticoagulation Reversal Agents;Critical Care Nursing Quarterly;2022-04

4. Enhancement and evaluation of a prescription audit system for direct oral anticoagulants using a check sheet;Journal of Pharmaceutical Health Care and Sciences;2021-06-01

5. Dabigatran Reversal With Idarucizumab in 2 Patients With Portal Vein Thrombosis Undergoing Orthotopic Liver Transplantation;Seminars in Cardiothoracic and Vascular Anesthesia;2021-01-04